LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told ... company's decision to stop selling its long-acting insulin Levemir, which is an analogue ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial form or as a disposable pen ... approved its short-acting insulin, Fiasp ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

“To address our current capacity constraints and reach more people with diabetes with our products in the future, our human insulin, which is currently delivered in pens and vials, will—over ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk is gradually ceasing the production of its human insulin pens, according to announcements made by the company. As it pivots towards manufacturing its newer obesity and diabetes injections ...

Novo Nordisk, in a strategic shift, is set to phase out the production of human insulin pens globally, although it remains unclear when this will occur. The pharmaceutical giant is redirecting its ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections. The ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...